Navigation Links
Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018
Date:11/9/2009

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new therapies will drive sales of HER2-targeting agents to grow by 3.3 percent per year from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Breast Cancer finds that significant declines in sales in the hormonal therapy and chemotherapy segments of the market will be offset by a 1.2 percent annual increase in breast cancer incidence in the world's major markets and by the launch and uptake of premium-priced agents. Emerging HER2-targeting therapies that are expected to launch by 2018 include Roche/Chugai's Omnitarg, Roche's T-DM1 and Wyeth's HKI-272.

The report also finds that sales of Roche/Chugai's Avastin for breast cancer will increase by four percent from 2008 to 2018, largely owing to greater uptake by patients with metastatic disease.

"Since its approval, Avastin has garnered substantial patient share in metastatic breast cancer, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where there is a significant need for effective therapeutic options," said Decision Resources Analyst Niamh Murphy, Ph.D. "However, many of the physicians we interviewed, particularly in Europe, are not very enthusiastic about Avastin for breast cancer because they consider its cost-benefit profile suboptimal."

According to the report, experts are enthusiastic about the launch and uptake of a novel class of breast cancer therapies -- the poly ADP-ribose polymerase (PARP) inhibitors. The PARP inhibitors represent a novel therapeutic strategy in DNA-repair-deficient tumors, such as triple-negative breast cancer.

"PARP inhibitors, which include Sanofi-Aventis's BSI-201 and AstraZeneca's olaparib, could dramatically improve prognoses for the woefully underserved patient subgroups with DNA-repair-deficient tumors," Dr. Murphy said.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources            Decision Resources, Inc.
    Christopher Comfort           Elizabeth Marshall
    781-296-2597                  781-296-2563
    ccomfort@dresources.com       emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Recession Continues to Depress Sales at Allied Healthcare Products
2. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
3. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
4. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
5. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
6. HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation
7. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
8. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
9. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
10. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
11. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... domain expertise for sponsors and CROs to speed clinical development, has released ... software platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting ...
(Date:4/25/2017)... ... 25, 2017 , ... Splashtop Inc. , the worldwide ... new addition to the Mirroring360 product family combines device screen mirroring with screen ... enables educators, business professionals and individuals to stream or mirror app screens, music, ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... A stressful ... at work can also decrease overall productivity and performance in the workplace. The goal ... , During the last few weeks of April, Clearview Resolution Services will be shutting ...
(Date:4/25/2017)... ... , ... The doctors at Wall Centre Dental are now expanding their practice ... sedation to receive dental care. The doctors offer three treatment options to put victims ... oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently welcoming ...
Breaking Medicine News(10 mins):